0 item(s)
View cart
You have no items in your shopping cart.
Description
BDTX-1535 is an orally bioavailable, brain-penetrating, mutation-selective, EGFR inhibitor with potential antitumor activity.
BDTX-1535 is a fourth-generation EGFR inhibitor that overcomes resistance to Osimertinib, the standard of care for EGFR-mutant non–small cell lung cancer (NSCLC). BDTX-1535 works well in NSCLC carrying C797S.
Importantly, BDTX-1535 can cross the blood-brain barrier and potentially treat CNS metastases in NSCLC. BDTX-1535 is also highly potent in EGFR-mutant glioblastoma cell lines and mouse models.
Technical Data
Product Name: BDTX-1535
Chemical Formula: C30H30ClFN6O2
Molecular Weight: 561.06
CAS#: 2607829-38-7
Appearance: Solid powder
Purity: > 99% by HPLC
Solubility: Soluble in DMSO
Storage: Room temperature for months, or -20ºC for 3 years.
Targets: EGFR
Synonym: BDTX-1535; BDTX1535; BDTX 1535
Chemical Name/IUPAC:(2E)-N-[4-][(3-Chloro-2-fluorophenyl)amino]-7-[2-][(1R,5S)-3-methyl-3-azabicyclo][3.1.0]hex-1-yl[C@]45CN(C)C[C@@]4([H])C5)/C=C/CN6CCOCC6
Synonym: BDTX-1535; BDTX1535; BDTX 1535
Chemical Name/IUPAC:(2E)-N-[4-][(3-Chloro-2-fluorophenyl)amino]-7-[2-][(1R,5S)-3-methyl-3-azabicyclo][3.1.0]hex-1-yl[C@]45CN(C)C[C@@]4([H])C5)/C=C/CN6CCOCC6
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
No data
